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Abstract
Background: Relation between pre-procedural selection of patients and the success rate after 
a single cryoballoon ablation (CAB) procedure is unknown.
Methods: CAB was performed in 378 (65% male, median age 58 years, 85% paroxysmal 
atrial fibrillation [AF]) consecutive patients with symptomatic and drug refractory AF. The 
combined ALARMEc (Atrial fibrillation type, Left Atrium size, Renal insufficiency, Meta-
bolic syndrome, cardiomyopathy) risk score was calculated for each individual patient. The 
end-point of the study was the first AF, atrial flutter or atrial tachycardia recurrence after the 
3-month blanking period in the 1-year follow-up since the index procedure, in the absence of 
anti-arrhythmic (class I and III) therapy.
Results: Single and multi-catheter approach was used in 79% and 21% of patients, respec-
tively. The acute success rate with single and multi-catheter approach was 79% and 99%, 
respectively. The overall 1-year success rate after a single CAB procedure was 70%. The 
1-year outcome was: 83%, 70%, 60%, 40% and 29% in patients with ALARMEc risk score:  
0, 1, 2, 3 and 5, respectively. Total rate of complications was 11%, including transient phrenic 
nerve palsy in 9.5% of cases.
Conclusions: Multi-catheter approach was needed in 21% of patients to achieve acute pulmo-
nary vein isolation. Patients with low (≤ 1) ALARMEc risk score, preferably young individuals 
with sole paroxysmal AF (ALARMEc = 0), are best candidates for CBA procedure. Performing 
CBA in patients with higher (> 2) ALARMEc risk score should be avoided. Phrenic nerve 
palsy was a transient complication. (Cardiol J 2015; 22, 2: 194–200)
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Introduction
The increase in number of catheter ablation of 
atrial fibrillation (AF) continues around the world 
[1]. The time-consuming, point-by-point radiofre-
quency ablation technique has been challenged by 
using novel technologies, like cryoballoon abla-
tion (CAB), aiming for a tantalizing “single-shot” 
approach to facilitate and speed up the invasive 
procedure [2]. The cryoballoon technology is lim-
ited to pulmonary vein isolation (PVI) and previous 
reports showed worse outcome in patients with 
non-paroxysmal atrial fibrillation (NPAF) accom-
panied by other comorbidity. Moreover, obtaining 
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satisfactory effects in case of variant anatomy of 
pulmonary veins (PVs) can be challenging with 
the need for additional “touch-up” with additional 
catheters [3].
We hypothesized that the acute and long-term 
success rate after a single CBA procedure is related 
to proper pre-procedural selection of patients.
Methods
Between 2005 and 2012 we enrolled 378 
consecutive patients (Table 1) with electrocardio-
graphic (ECG)-documented AF on at least 2 ECGs 
in last 3 months, symptomatic AF, drug-refractory 
AF, age ≥ 18 and ≤ 80 years, signed informed con-
sent. Exclusion criteria were as follows: reversible 
cause of AF (such as hyperthyroidism), moderate-
to-severe valvular stenosis or insufficiency, previ-
ous myocardial infarction, any congenital heart 
disease, left ventricular ejection fraction < 50%, 
coronary artery bypass graft surgery within the last 
3 months, chronic obstructive pulmonary disease 
treated with beta-sympathomimetic drugs, severe 
respiratory insufficiency, known bleeding diathesis, 
intolerance of heparin or oral anticoagulation, at-
tempted AF ablation in the past, left atrial throm-
bus, pregnancy or breastfeeding, New York Heart 
Association class IV, severe comorbidity, abuse of 
drugs of alcohol, the diameter of any PV or common 
ostium > 27 mm in magnetic resonance imaging, 
no signed informed consent.
Combined ALARMEc risk score
The ALARMEc (Atrial fibrillation type, Left 
Atrium size, Renal insufficiency, Metabolic syn-
drome, cardiomyopathy) combined risk score was 
calculated using the formula (Table 2), where Bi 
is regression coefficient by significant predictor 
Xi (all predictors were dichotomized) in Cox re-
gressions model. For simple usage the calculated 
ALARMEc risk score  was rounded off to the 
nearest integer.
The combined ALARMEc risk score was 
proved to be an effective tool for discrimination 
of patients outcome after any ablation procedure 
[4, 5].
We calculated ALARMEc risk score for each 
individual patient.
Table 1. Baseline characteristics (n = 478). Continuous data were described as median, lowest  
(interquartile range [IQR] 25) and highest (IQR75) quartiles.
Male 244 (64.55%)
Age [years], median (IQR) 58 (49;65)
History of atrial fibrillation [years], median (IQR) 5.27 (2.16;10.00)
Paroxysmal atrial fibrillation 320 (84.65%)
Body mass index [kg/m2], median (IQR) 26.71 (24.51;29.55)
Echocardiography:
Left atrium short diameter [mm], median (IQR) 38 (36;40)
Left atrium long diameter [mm], median (IQR) 51 (47;55)
Left atrium area [mm], median (IQR) 19.24 (17.28;22.04)
Normalized left atrium area, median (IQR) 9.54 (8.44;10.82)
Left ventricular ejection fraction [%], median (IQR) 62 (57;62)
Medical history:
Glomerular filtration rate [mL/min], median (IQR) 92.1 (80.30;106.52)
Hypertension 223 (58.99%)
Coronary artery disease 26 (6.88%)
Diabetes mellitus 19 (5.03%)
Metabolic syndrome 131 (34.66%)
Antiarrhythmic drugs at inclusion:
Class I 180 (47.62%)
Class II 240 (63.49%)
Class III 95 (25.13%)
Amiodarone 39 (10.32%)
Dronedaron 30 (7.94%)
Sotalol 26 (6.88%)
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Pre-ablation
Medical history was obtained during ambula-
tory visits with a thorough review of the medical re-
cords including ECGs and Holter-ECG recordings 
showing episodes of AF. All patients gave written 
informed consent. The study was approved by the 
local institutional Ethics Committee. Oral antico-
agulation was stopped 3 days before intervention 
and replaced by subcutaneous low-molecular-weight 
heparin. Antiarrhythmic drugs were discontinued 
at least 3 days before ablation. Beta-blockers were 
allowed according to the protocol.
All patients underwent echocardiography 
to determine left atrium (LA) diameter and ex-
clude LA thrombus. The LA size was assessed by 
measurement of short and long axis in the apical 
4-chamber view.
Intervention and post-ablation  
management
The procedure was previously described [3, 6]. 
After the transseptal punctures were performed, 
heparin was introduced with the aim of keeping 
the activation clotting time > 300 s throughout 
the whole procedure. Briefly, we used 23- and/or 
28-mm cryoballoon (Arctic Front™, Medtronic-
Cryocath). The single application time was 
240–300 s. During CBA of the right-sided PVs, 
unaffected phrenic movement was monitored by 
both continuous phrenic nerve stimulation and 
continuous monitoring of spontaneous breath-
ing. An observation period after initial isolation 
to check for recurrence of PV conduction was 
30 min. If PVI could not be achieved with a first-
choice cryoballoon size, we additionally used 
the different sized one. If PVI could not be con-
firmed after 5 consecutive applications per PV with 
any balloon, an 8-mm tip cryoablation catheter 
(FreezorMAX™, MedtronicCryocath) was used 
for touch-up ablation to complete PVI which was 
verified as complete elimination of all PV signals 
at the antral or ostial level. Additionally, exit and 
entrance-block of all PVs were confirmed by pacing 
maneuvers, as previously described.
After the procedure, intravenous heparin 
was continued to achieve a partial thromboplastin 
time of 60–80 s, followed by oral anticoagulation 
with coumadin, for at least 3 months, targeting 
an international normalized ratio of 2–3. Antiar-
rhythmic treatment was stopped. Beta-blockers 
were allowed during the follow-up.
Follow-up
Our strict follow-up protocol fulfills latest rec-
ommendations [7]. After discharge from the hospi-
tal, patients were scheduled for quarterly follow-up 
visits. Late follow-up (> 1 year post-intervention) 
was performed once a year. Seven-day Holter- 
-ECG recordings were obtained at each follow-up 
visit. Each patient, in case of any palpitations, was 
instructed to have ECG performed for confirming 
or excluding atrial fibrillation, atrial flutter or atrial 
tachycardia (AFLAT).
Statistical analysis
The study was designed as an observational 
cohort study with the analyzed period of one year. 
The end-point of the study was the first AFLAT-
-recurrence after the 3-month blanking period in 
the 1-year follow-up since the index procedure, 
in the absence of antiarrhythmic drugs (class I 
and III) therapy. Kaplan-Meier univariate analy-
sis was used to estimate AFLAT-free survival. 
Continuous data were described as median, 
lowest (IQR25) and highest (IQR75) quartiles. 
The discrete variables were given in number and 
percentage. The differences were considered 
significant be error probability p < 0.05.
Table 2. Calculation of the ALARMEc risk score. 
ALARMEc risk score Xi Bi
A Type of atrial fibrillation Non-proxymal AF –0.611
LA Size of left atrium NLA ≥ 11.5 –0.366
R Renal function GFR < 68 mL/min –0.398
ME Metabolic syndrome Yes –0.324
c Dilated/hypertrophic cardiomyopathy Yes –0.445
AF — atrial fibrillation; GFR — glomerular filtration rate; NLA — normalized left atrium area
ALARMEc =                                 – 0.5)* – 10
exp (Â BiXi)
1 + exp (Â BiXi)
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Table 3. Acute isolation of pulmonary veins (PVs) related to PVs anatomy and type and number of 
catheter used (p = 0.149). Consequently, 1,860 out of 1,871 (99.4%) PVs were isolated with single-  
or multi-catheter approach.
All patients
N = 378 (100%)
Typical PVs anatomy
N = 341 (90.21%)
Atypical PVs anatomy
N = 37 (9.79%)
Single balloon approach: 300 (79.36%) 270 (74.07%) 30 (7.93%)
   23-mm CBA 52 (13.76%) 51 (13.49%) 1 (0.26%)
   28-mm CBA 248 (65.61%) 219 (57.93%) 29 (7.67%)
Multi-catheter approach* 78 (20.63%) 71** (18.78%) 7 (1.85%)
*Additional catheter (other sized cryoballoon and/or FreezorMax™) was needed, including 29 (7.67%) in whom both two sized balloons and 
FreezorMax™ was used; **45 patients with typical anatomy but critical pulmonary veins angulation; CAB — cryoballoon ablation
Table 4. The incidence of complications.
N = 378 Tamponade Pericardial effusion TIA Stroke PNP All complications Total
N (%) 2 (0.6%) 2 (0.6%) 1 (0.3%) 1 (0.3%) 36 (9.5%) 42 (11.1%) 378 (11.1%)
TIA — transient ischemic attack; PNP — phrenic nerve palsy
Figure 1. The 1-year outcome after a single cryoballoon ablation procedure related to patients’ ALARMEc (Atrial fibril-
lation type, Left Atrium size, Renal insufficiency, Metabolic syndrome, cardiomyopathy) risk score; AFLAT — atrial 
fibrillation, atrial flutter or atrial tachycardia.
Results
In total, 378 consecutive patients were treated 
(Table 3). Consequently, 1,502 out of 1,512 (99.3%) 
PVs were isolated. The median procedure and 
fluoroscopy time was 3.8 h (3.0;4.5) and 37.8 min 
(27.0;55.2), respectively.
Peri-procedural complications are presented 
in Table 4. Right phrenic nerve palsy (PNP) was 
observed in 36 (9.5%) patients during cryoablation 
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of the right superior PV. PNP resolved in 14 cases 
during the procedure. An early termination of 
cryoenergy application during right phrenic pacing 
did not prevent the subsequent occurrence of PNP. 
In all other patients, full re-covery of right phrenic 
function was observed during 1-year follow-up. We 
observed higher occurrence of PNP in patients 
treated with the 23 mm balloon as compared with 
28 mm: 24 vs. 12 patients, respectively.
The overall 1-year success rate after a single 
CAB procedure was 66.9%. The 1-year outcome 
related to calculated ALARMEc risk score is 
presented in Figure 1. The most favorable 1-year 
outcome was observed in patients with ALARMEc 
scores 1 and 2 (83% and 70% AFLAT-free, re-
spectively). On the contrary, individuals with 
lowest ALARMEc scores (3 and 4; 40% and 29% 
AFLAT-free, respectively) should not be rather the 
candidates for CAB.
Discussion
The cryoballoon technology is limited to PVI. 
Our results show that adequate pre-procedural se-
lection of patients and focusing on individuals with 
low ALARMEc risk score, is crucial both for acute 
PVI and long-term outcome after CBA procedure.
Acute success
The isolation of PVI is a cornerstone of CBA. 
Previous analysis showed that acute PVI, with 
a single cryoballoon catheter only, could be com-
pleted in 78% of patient [8]. Better acute results 
were reported in studies in which additional cry-
oballoon catheter (98.7%) or concomitant focal 
ablation (98.9%) was used [8]. Our results are 
comparable. We were able to isolate all PVs in 79% 
of patients with a single balloon only. Additional 
catheter allowed for PVI in 99.3%.
Pre-procedural imaging of PVs anatomy seems 
to be crucial, especially for centers restricted to 
1 cryoballoon catheter only. Failure in acute PVI 
could result not only in AF-recurrence but also in 
LA tachycardia related to CBA [9, 10]. Mikhaylov 
et al. [9] showed that atrial tachycardia after CBA 
was more frequently observed in patients in whom 
procedure was more laborious (atypical anatomy 
and need for additional “touch-up” lesions) [10].
Recently Goginn et al. [11] has showed that 
the mechanisms leading to PVs conduction recov-
ery were difficulty in correct positioning of the 
cryoballoon and geometrical mismatch between 
the cryoballoon and the PV ostium. The good cryo-
balloon-tissue contact is an important parameter 
influencing the cryoenergy-related lesion. This 
parameter is likely involved in the PV reconduction 
process, especially at PV with difficult geometries 
[11]. Optimization of tissue contact may require 
utilization of technical maneuvers [11, 12], differ-
ent sized balloons [3, 6, 8, 13], and “touch-up” focal 
lesions [3, 6, 8, 13–15]. Moreover, peri-procedural 
PNP results in abrupt interruption of cryoenergy 
application by an operator which can be the next 
cause of not-complete acute PVI success. Still, 
in our series, we have not found any differences 
in outcome comparing patients with and without 
transient PNP during CBA procedure.
ALARMEc risk score and long-term success
In 1998, Haissaguerre et al. [16] showed that 
PVs have been the crucial source of the triggers 
that initiate AF and electrical PVI could be an ef-
fective therapeutic option for AF. Currently we 
know that AF has a tendency to becoming more 
persistent over time [17]. The progression of 
electrical and further structural remodeling of atria 
promotes both reentry and ectopic activity which 
can serve not only as substrate but also as triggers 
for AF [17]. Sole PVI has low effectiveness in such 
electrically and structurally changed environment.
Many factors (type of AF, LA size, age, sleep 
apnea and obesity, hypertension, LA fibrosis de-
tected by magnetic resonance imaging, diabetes, 
a rise in right atrium magnetic strength) have 
been proposed as predictors of a poorer outcome 
after PVI [18, 19] but the discrepancies among 
authors [20–25] showed the complicated nature 
of already ablated atrial tissue. We applied a com-
bined ALARMEc risk score which effectively 
discriminates patient outcome after any ablation 
procedure [4, 5]. Our data show that patients with 
low (≤ 1) ALARMEc risk score have most favorable 
outcome. In individuals with high (≥ 3) ALARMEc 
risk score the outcome is poor.
There are many possible reasons that patients 
with low (≤ 1) ALARMEc risk score may have 
such a good outcome. This group has not-enlarged 
atria and paroxysmal form of AF. The probability of 
deep remodeling process, in such settings, is low 
and the development of AF is rather trigger- and 
not substrate-dependent. Most triggers originate 
in LA-PVs junction [26]. PVI-focused CBA, which 
eliminates triggers, and partially substrate located 
near LA-PVs junction, results in high success rate in 
such patients. Failure of PVI in this group is rather 
a result of incomplete isolation of LA-PVs triggers 
or existing non-LA-PVs triggers. Moreover, the 
combination of normal-sized LA and relatively big 
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balloon may result not only in ostial circumferential 
but also in PVI by ipsilateral antral block ablation, 
which might further improve the clinical outcome 
[27]. Comparable good results in similar low risk 
patients, were recently showed by others [15, 28]. 
Moreover, CBA procedure was proposed as first-line 
therapy in patients with lone paroxysmal AF [15]. 
Indeed, our results show that it can be a case for 
patients with lowest (= 0) ALARMEc risk score.
Patients with moderate (= 2) ALARMEc risk 
score are at the borderline of persistency of AF. 
The ablation procedure should be advocated in 
this group to interrupt a process of continuous 
remodeling. We show that PVI with CBA will have 
moderate 1-year success rate. More invasive ap-
proach, with additional lesions within atria, should 
be rather considered to further improve the out-
come in this cohort.
Patients with high (= 3) and very high (= 4) 
ALARMEc risk score, i.e. patients with non-par-
oxysmal AF with concomitant comorbidity which 
further promotes atrial remodeling, had poor 1-year 
outcome. Steep drop in AFLAT-free survival was 
noted since the first months after the blanking 
period (Fig. 1). Other authors also showed very 
poor outcome in similar cases [29]. These patients 
are rather candidates for radiofrequency ablation 
with additional substrate modifications or in severe 
cases for rate control only.
Complications
The incidence of major complications was 
comparable to previously published data [8]. We 
noted peri-procedural PNP in 9.52% of cases. Still, 
in all our patients, the full recovery from PNP, 
between some minutes after cessation of cryoen-
ergy application up to 1 year after the ablation 
procedure, was observed. Nevertheless, despite 
different safety approaches proposed recently, the 
problem of PNP has not been eliminated [30].
Clinical implications
Firstly, selection of patients is crucial. Patients 
with typical anatomy and lower ALARMEc risk 
score appear to be the first line candidates for CBA 
procedure.
Secondly, more than one single cryoballoon can 
be needed to complete PVI, especially in patients 
with atypical anatomy of PVs.
Thirdly, patients should be aware of possible 
procedure-related complications, including PNP.
Finally, ongoing surveillance is warranted, 
even if CBA was deemed initially successful. In-
cidence of late recurrence may be related to the 
extent of ECG monitoring and earlier recurrence 
may be missed in selected patients with no or 
minimal symptoms [7]. Additionally, procedure of 
ablation is one of many steps in the process of treat-
ing a patient with AF. Focusing on controllable risk 
factors, like renal insufficiency and components 
of metabolic syndrome, could shift a patient to 
a lower ALARMEc risk group and further improve 
the outcome.
Limitations of the study
This is a single-center, observational cohort 
report with the inherent limitations of this study 
design. However, there was no selection bias for 
study inclusion since all consecutive patients 
undergoing cryoballoon ablation procedure were 
included for analysis.
The presented data reflect our experience 
with cryoballoon technique gained in a high vol-
ume center by operators already experienced in 
standard and advanced ablation procedures. The 
results should not be extrapolated to low-volume 
centers and unexperienced operators.
Conclusions
Cryoballoon ablation, aimed at PVI, allowed 
to achieve satisfactory outcome in the selected 
population of patients.
Acute single-cryoballoon PVI success was 
high (79%) but not complete. Multi-catheter ap-
proach was needed in 78 (20.6%) patients.
Patients with low (≤ 1) ALARMEc risk score, 
preferably young individuals with sole paroxys-
mal AF (ALARMEc = 0), are best candidates for 
CBA procedure. Contrary, performing CBA in 
patients with high ALARMEc risk score should 
be avoided.
PNP was a transient complication. Other se-
rious complication with the need for intervention 
were relatively rare.
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